Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form 4

HOLLIS EDEN PHARMACEUTICALS INC /DE/

Form 4

January 22, 2008

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

Expires:

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

3235-0287 Number: January 31,

2005

OMB APPROVAL

Section 16. Form 4 or Form 5

SECURITIES

Estimated average burden hours per

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

response... 0.5

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

WEBER ROBERT W

Symbol

HOLLIS EDEN PHARMACEUTICALS INC /DE/

(Check all applicable)

[HEPH]

(Last) (First) (Middle) 3. Date of Earliest Transaction

Director 10% Owner X_ Officer (give title Other (specify below)

(Month/Day/Year) 01/17/2008

CAO & VP Controller

4435 EASTGATE MALL, SUITE

(Street)

400

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

(Instr. 8)

X Form filed by One Reporting Person Form filed by More than One Reporting

(Instr. 4)

6. Individual or Joint/Group Filing(Check

SAN DIEGO, CA 92121

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year)

Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D)

5. Amount of Securities Beneficially Owned

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect Beneficial Ownership

(Instr. 4)

(A)

(Instr. 3, 4 and 5)

Following Reported Transaction(s)

(Instr. 3 and 4) Code V Amount (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amour or Number of Shar
Stock Option (Right to Buy)	\$ 1.62	01/17/2008		A	25,000		<u>(1)</u>	01/16/2018	Common Stock	25,00
Stock Option (Right to Buy)	\$ 2.25	01/17/2008		D(2)		30,350	(2)	02/25/2008	Common Stock	30,35
Stock Option (Right to Buy)	\$ 2.25	01/17/2008		A(2)	30,350		(2)	02/25/2013	Common Stock	30,35
Stock Option (Right to Buy)	\$ 1.62	01/17/2008		A		3,000	(3)	01/16/2018	Common Stock	3,00
Stock Option (Right to Buy)	\$ 1.62	01/17/2008		A		25,000	<u>(4)</u>	01/16/2018	Common Stock	25,00

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

WEBER ROBERT W 4435 EASTGATE MALL, SUITE 400 SAN DIEGO, CA 92121

CAO & VP Controller

Signatures

Robert W. 01/22/2008 Weber

**Signature of
Reporting Person

Date

Reporting Owners 2

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the Stock Option shall vest and become exercisable on the first anniversary of the date of grant. The balance of the shares shall vest and become exercisable in 36 equal monthly installments thereafter.
- Amendment of an outstanding Stock Option in order to extend the termination date of the exercise period for the remaining 30,350 shares subject to the Stock Option from February 26, 2008 to February 26, 2013 resulting in deemed cancellation of the Stock Option and grant of a replacement Stock Option. The Stock Option was originally granted on February 26, 2003 for 40,000 shares and was fully vested and exercisable upon grant.
- (3) Fully vested and exercisable upon grant.
- (4) The shares subject to the Stock Option shall vest and become exercisable in 12 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.